ReviewNature reviews. Clinical oncology2021
Nasopharyngeal carcinoma: an evolving paradigm.
Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07661771 (Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma), which is not on this map. Cited by 316 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma: A Non-Inferiority, Multicenter, Randomized Phase 3 Trial
Who cites it
316 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Pooled it
- SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Comparative study of three treatment approaches on overall survival and treatment response in nasopharyngeal carcinoma patients: network meta-analysis of RCTs (4221 patients).Frontiers in oncology · 2026Pooled it
- Immune checkpoint inhibitor integration in locoregionally advanced nasopharyngeal carcinoma: a prospective evidence synthesis on efficacy, safety, and therapeutic optimization.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Pooled it
- Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Pooled it
- [Frontiers in medicine · 2024Pooled it
- Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.Journal for immunotherapy of cancer · 2025Trial
- Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial.BMJ (Clinical research ed.) · 2025Trial
- Trial
- Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).Cancer immunology, immunotherapy : CII · 2025Trial
- A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.Cell reports. Medicine · 2024Trial
- Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma.Cancer science · 2024Trial
- Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- A Multimodal Machine Learning Model Combining Dosimetric and Radiomic Shape Features for Predicting Moderate‑to‑Severe Xerostomia After Radiation Therapy for Nasopharyngeal Carcinoma.Advances in radiation oncology · 2026Article
- CXCL11 secreted by cancer-associated fibroblasts promotes nasopharyngeal carcinoma progression via CXCR3/PD-L1 axis.Cell adhesion & migration · 2026Article
- Proton Versus Photon Radiation Therapy for Nasopharyngeal Carcinoma.Journal of neurological surgery. Part B, Skull base · 2026Article
- Integrative microbiome and functional profiling identifymSystems · 2026Article
256 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past three decades have borne witness to many advances in the understanding of the molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-associated cancer endemic to southern China, southeast Asia and north Africa. In this Review, we provide a comprehensive, interdisciplinary overview of key research findings regarding NPC pathogenesis, treatment, screening and biomarker development. We describe how technological advances have led to the advent of proton therapy and other contemporary radiotherapy approaches, and emphasize the relentless efforts to identify the optimal sequencing of chemotherapy with radiotherapy through decades of clinical trials. Basic research into the pathogenic role of EBV and the genomic, epigenomic and immune landscape of NPC has laid the foundations of translational research. The latter, in turn, has led to the development of new biomarkers and therapeutic targets and of improved approaches for individualizing immunotherapy and targeted therapies for patients with NPC. We provide historical context to illustrate the effect of these advances on treatment outcomes at present. We describe current preclinical and clinical challenges and controversies in the hope of providing insights for future investigation.
Indexed as
Identifiers
34194007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.